Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 2 |
2021 | 1 |
2022 | 2 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
xiaowei ha
(2 results)?
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Ann Hematol. 2023 Feb;102(2):311-321. doi: 10.1007/s00277-022-05071-8. Epub 2023 Jan 13.
Ann Hematol. 2023.
PMID: 36635381
Free PMC article.
Clinical Trial.
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, Díez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, Verma A.
Komrokji RS, et al. Among authors: ha x.
Leukemia. 2022 May;36(5):1432-1435. doi: 10.1038/s41375-022-01521-4. Epub 2022 Feb 26.
Leukemia. 2022.
PMID: 35220402
Free PMC article.
No abstract available.
Item in Clipboard
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Zeidan AM, Platzbecker U, Garcia-Manero G, Sekeres MA, Fenaux P, DeZern AE, Greenberg PL, Savona MR, Jurcic JG, Verma AK, Mufti GJ, Buckstein R, Santini V, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji RS.
Zeidan AM, et al. Among authors: ha x.
Blood. 2022 Nov 17;140(20):2170-2174. doi: 10.1182/blood.2022016171.
Blood. 2022.
PMID: 35797468
Free PMC article.
Item in Clipboard
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
Oliva EN, Platzbecker U, Garcia-Manero G, Mufti GJ, Santini V, Sekeres MA, Komrokji RS, Shetty JK, Tang D, Guo S, Liao W, Zhang G, Ha X, Ito R, Lord-Bessen J, Backstrom JT, Fenaux P.
Oliva EN, et al. Among authors: ha x.
J Clin Med. 2021 Dec 22;11(1):27. doi: 10.3390/jcm11010027.
J Clin Med. 2021.
PMID: 35011768
Free PMC article.
Item in Clipboard
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
Buchanan RW, Panagides J, Zhao J, Phiri P, den Hollander W, Ha X, Kouassi A, Alphs L, Schooler N, Szegedi A, Cazorla P.
Buchanan RW, et al. Among authors: ha x.
J Clin Psychopharmacol. 2012 Feb;32(1):36-45. doi: 10.1097/JCP.0b013e31823f880a.
J Clin Psychopharmacol. 2012.
PMID: 22198451
Clinical Trial.
Item in Clipboard
Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia.
Cazorla P, Mackle M, Zhao J, Ha X, Szegedi A.
Cazorla P, et al. Among authors: ha x.
Neuropsychiatr Dis Treat. 2012;8:247-57. doi: 10.2147/NDT.S29891. Epub 2012 Jun 15.
Neuropsychiatr Dis Treat. 2012.
PMID: 22745558
Free PMC article.
Item in Clipboard
Cite
Cite